4.5 Article

Development of an updated, standardized, patient-centered outcome set for lung cancer

Journal

LUNG CANCER
Volume 173, Issue -, Pages 5-13

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2022.08.021

Keywords

Lung cancer; Core outcome set; Patient -reported outcomes; Quality of life; Value -based healthcare

Ask authors/readers for more resources

This study aimed to develop a patient-centered core outcome set (COS) for lung cancer to capture the impact of lung cancer and treatments from the patient perspective. Through multiple stages, the study finalized a lung cancer COS including case-mix factors, patient-reported outcomes related to health-related quality of life, and clinical outcomes. The results will support standardized lung cancer measurement and empower patients in managing their healthcare.
Background: In 2016, the International Consortium for Health Outcomes Measurement (ICHOM) defined an international consensus recommendation of the most important outcomes for lung cancer patients. The European Health Outcomes Observatory (H2O) initiative aimed to develop an updated patient-centered core outcome set (COS) for lung cancer, to capture the patient perspective of the impact of lung cancer and (novel) treatments using a combination of patient-reported outcome (PRO) instruments and clinical data as a means to drive value -based health-care. Material and methods: An international, expert team of patient representatives, multidisciplinary healthcare professionals, academic researchers and pharmaceutical industry representatives (n = 17) reviewed potential outcomes generated through literature review. A broader group of patients/patient representatives (n = 31), healthcare professionals / academic researchers (n = 83), pharmaceutical industry representatives (n = 26), and health authority representatives (n = 6) participated in a Delphi study. In two survey rounds, participants scored the relevance of outcomes from a preliminary list. The threshold for consensus was defined as >= 70 % of participants scoring an outcome as highly relevant'. In concluding consensus-meeting rounds, the expert multi-disciplinary team finalized the COS. Results: The preliminary list defined by the core group consisted of 102 outcomes and was prioritized in the Delphi procedure to 64. The final lung cancer COS includes: 1) case-mix factors (n = 27); 2) PROs related to health-related quality of life (HRQoL) (n = 25); 3) clinical outcomes (n = 12). Patient-reported symptoms beyond domains included in the ICHOM lung cancer set in 2016 were insomnia, nausea, vomiting, anxiety, depression, lack of appetite, gastric problems, constipation, diarrhoea, dysphagia, and haemoptysis. Conclusions: We will implement the lung cancer COS in Europe within the H2O initiative by collecting the outcomes through a combination of clinician-reported measures and PRO measures. The COS will support the adoption and reporting of lung cancer measures in a standardized way across Europe and empower patients with lung cancer to better manage their health care.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available